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ABSTRACT 
 
Staphylococcus aureus (n=157) isolated from intramammary infections in Argentine dairy areas were 
evaluated for presence of cap5 and cap8 loci. Isolates carrying cap5 and cap8 were serotyped using specific 
antisera. Sixty four percent of the isolates were genotyped as cap5 or cap8 and 50% of them expressed CP5 
or 8.  
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Staphylococcus aureus capsular polysaccharides have 
been shown to confer resistance to phagocytosis by 
polymorphonuclear neutrophils (PMN), which are considered 
the main mammary gland line of defense against invading 
pathogens (5). Conversely, antibodies against CPs have a 
protective effect since they can opsonize encapsulated S. 
aureus from bovine origin for phagocytic killing by PMN (5).  
The existence of 11 CP serotypes has been proposed (13); 
however, only four types (CP1, CP2, CP5 and CP8) have been 
chemically characterized. Among them, CP5 and CP8 are the 
predominant serotypes in S. aureus isolated from human and 
bovine infections (13). Distribution of CP serotypes among S. 
aureus isolates from bovine milk from different countries 
shows variability (6, 15, 23). A study carried out in Argentina 
found that only 14% from 195 S. aureus isolates were typeable 
by serological methods (21). However, more than 70% of those 
isolates belonged to one province and only 9 isolates came 
from two provinces that concentrate about 60% of Argentina 
dairy production.  
Capsular polysaccharides in vitro expression does not 
necessarily correlate with expression under in vivo conditions 
(11, 13). Therefore, surveys of CP prevalence taking into 
account only the in vitro phenotype, could underestimate the 
true distribution of virulent CP strains among a bacterial 
population. Up to now, the reports of CP prevalence have been 
mainly performed by in vitro phenotype analysis and only in 
few studies involving S. aureus from bovine origin, a subset of 
phenotyped isolates was typed by genetic methodology (21, 
23). 
Protection afforded by antibodies against CPs is related to 
their prevalence and type distribution in the population of 
isolates present in different regions (10). Therefore, the latter
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information is of paramount importance to estimate the 
usefulness of incorporating these components in a vaccine 
formulation. The aim of this study was to determine the 
prevalence and distribution of capsular genotype and 
phenotype of S. aureus isolated from bovine IMI in the four 
main dairy provinces of Argentina by genotypic and 
phenotypic methods. 
One hundred and fifty seven S. aureus isolates were 
obtained between 2004 and 2007 from mammary secretion of 
cows with clinical or subclinical IMI, including a maximum 
number of 3 isolates from the same dairy herd. Isolates were 
confirmed to be S. aureus on the basis of conventional 
biochemical reactions. Isolates belonged to 83 dairy farms 
located in four Argentine provinces that concentrate more than 
90% dairy production of the country: Santa Fe (n=91), Buenos 
Aires (n=31), Córdoba (n=22) and Entre Ríos (n=13). From 
these isolates, 43 were from clinical and 91 from subclinical 
IMI; while for the remaining 23 isolates, the clinical origin was 
not determined. Clinical IMI was defined as presence of 
clinical signs in the mammary quarter (swelling, heat, pain) 
and/or changes in the appearance of milk; while subclinical 
IMI was defined as absence of clinical signs but somatic cell 
counts > 200,000 cells/ml. 
Genomic DNA was extracted from each isolate with a 
standard phenol-chloroform procedure (14). The presence of 
cap5k and cap8I loci was evaluated in all the isolates by 
Polymerase Chain Reaction (PCR). PCR was performed using 
genomic DNA as a template in a total volume of 25µl 
containing: 1x PCR buffer, 2mM MgCl2, 0.25 mM dNTPs 
(Genbiotech, Buenos Aires, Argentina), 1U/µl Thermus 
aquaticus DNA polymerase (PB-L, Argentina) and 0.2 µM of 
the primers Cap5k1 (5’-GTCAAAGATTATGTGATGCTAC 
TGAG-3´), Cap5k2 (5´-ACTTCGAATATAAACTTGAATCA 
ATGTTATACAG-3´), Cap8k1 (5´-GCCTTATGTTAGGTGA 
TAAACC-3´), Cap8k2 (5´-GGAAAAACACTATCATAGCA 
GG-3´) (Invitrogen Argentina, Buenos Aires) as described by 
Verdier et al. (24). Amplification was carried out on GeneAmp 
PCR System (Applied Biosystems, USA) using a program as 
follows: an initial 5-min denaturation step at 94°C, followed by 
30 cycles of 30 s of denaturation at 94°C, 30 s of annealing at 
50°C, and 1 min of extension at 72°C; with a final extension 
step at 72°C for 5 min. PCR products were analyzed by 
electrophoresis on ethidium bromide-stained 1.5% agarose gels 
(Biodynamics, B.A. Argentina). The sizes of the amplicons 
were 361 bp for capsular type 5 and 173 bp for capsular type 8. 
Bacterial suspensions for preparation of typing sera were 
made from cultures of prototype S. aureus strains CP5 
(Reynolds) and CP8 (Becker). These strains were isolated in 
1979 from blood cultures at Kaiser permanent Hospital, North 
Hollywood, California (9) and were a kind gift from Dr. B. 
Poutrel (INRA, Nouzilly, France). Bacteria were grown on 
Columbia agar (Britania, Buenos Aires) supplemented with 
2.5% NaCl, harvested and inactivated following previously 
described conditions (8). Two New Zealand white rabbits 
weighing 3 kg were immunized with each bacterial prototype 
according to the scheme described by Karakawa et al. (8, 12). 
Each rabbit serum was absorbed with S. aureus strain 57, to 
remove antibodies to noncapsular antigens as previously 
described (8), aliquoted and stored at -70°C. CP from prototype 
strains 5 and 8 and all isolates typed by genetic method 
(n=101) were isolated as described by Fattom et al. (3). 
Polysaccharides concentration was determined by phenol-
sulphuric acid method (2), and presence of CP was visualized 
by SDS-Page and silver stain. Absence of proteins was verified 
by bicinchoninic acid assay (20) and SDS-Page followed by 
Coomassie Blue stain. ELISA assays were performed as 
follows: 5µg of purified CPs from isolates genotyped as 
carrying cap5 and cap8 were used as antigens to sensitize 96-
well plates. Plates were blocked with PBS-powdered milk (5%) 
and incubated with CP5 or CP8 antisera (1/200), respectively. 
Finally, a goat anti-rabbit IgG conjugated to alkaline 
peroxidase was used as secondary antibody, and the reaction 
was developed with TMB (Zimed). All incubations were 
carried out at 37°C, for 60 minutes. Optical Densities (OD) 
were measured at 450 nm in an ELISA plate reader (Molecular 
Device). Chi square test was used to compare percent 
 1012
Camussone, C. et al.         Detection of capsular polysaccharides in S. aureus 
 
 
distribution of capsular types between provinces and to assess 
association between percent distributions of capsular types 
with regard to clinical origin of the isolates. 
Sixty four percent of the isolates were typeable by PCR 
with specific primers for loci cap5 or cap8; being the rest of 
the isolates nontypeable (NT). Eighty three (52.87%) isolates 
were genotyped as cap5 whereas eighteen (11.4%) as cap8. 
None of the isolates positive for either cap5 or cap8 genes was 
found to amplify both genes, confirming specificity of PCR 
used. Distribution of genotypes among isolates originated in 
different geographical areas is shown in Table 1. The prevalent 
capsular type among isolates from Córdoba, Santa Fe and Entre 
Ríos was cap5. Conversely, the majority of isolates from 
Buenos Aires were NT, while type 5 was predominant among 
typeable isolates from this province. CP genotype distribution 
and percent of NT isolates varied between provinces; however, 
differences were not significant (P=0.227). More than 50% of 
the isolates from each province could be genotyped by the PCR 
methodology. Among isolates from clinical IMI, 31 (72.1%) 
were genotyped either as cap5 or cap8, while only 12 (27.9%) 
were NT. Among 91 isolates from subclinical IMI, 53 (58.2%) 
were typed as cap5 or 8 and 38 (41.8%) were NT (Table 2). 
Differences between percentages of typeable isolates according 
to the clinical origin were not significant (P=0.12).  
 
Table 1. Distribution of capsular polysaccharide genotypes and phenotypes 5 and 8 among Staphylococcus aureus isolated from 
bovine intramammary infections in four Argentinean provinces. 
References: NT: nontypeable. 
No differences in CP genotype (P = 0.227) or phenotype (P = 0.179) distribution were found between provinces. 
 
Table 2. Distribution of S. aureus isolate types CP5 or CP8, according to mastitis clinical origin.  
 
 
 
 
References: NT: nontypeable. 
No statistical association between genotype (P =0.12) or phenotype (P=0.262) and clinical origin of the isolate 
was not found. 
 
 
The isolates genotyped as cap5 and cap8 were then tested 
with anti-CP5 and anti-CP8, respectively. The results of 
serotyping are shown in Table 1. Fifty percent of isolates 
genotyped as cap5 and cap8 were shown to produce CPs by 
ELISA for detecting either capsular type. Thirty nine isolates 
(38.6%) reacted to anti-CP5 serum and 12 (11.9%) to anti-CP8. 
From 83 isolates genotyped as cap5, 39 (46.9%) were capable 
of expressing CP; while from 18 isolates genotyped as cap8, 12 
(66.6%) were capable of expressing CP. 
A statistical association between the expression of CP5 or 
CP8 capsules and clinical origin of the isolate was not found 
(Table 2). From 84 isolates genotyped as cap5 and cap8 for 
which clinical status was known, 31 (37%) where from clinical 
IMI, and among these isolates 14 (45.2%) and 17 (54.8%) were 
serotypeable and non serotypeable, respectively. Among 
isolates from subclinical origin, 53 from the 84 isolates were 
Provinces 
Santa Fe Entre Ríos Córdoba Buenos Aires Total 
 Genotype Phenotype Genotype Phenotype Genotype Phenotype Genotype Phenotype Genotype Phenotype
cap5 (%) 46 (50.5) 19 (33.3) 10 (76.9) 6(54.5) 16 (72.7) 6(37.5) 11 (35.5) 8(47.1) 83 (52.9) 39(38.6) 
cap8(%) 11 (12.1) 8(14.0) 1 (7.7) 0 0 (0) 0 6 (19.3) 4(23.5) 18 (11.4) 12(11.9) 
NT(%) 34 (37.4) 30(52.7) 2 (15.4) 5(45.5) 6 (27.3) 10(62.5) 14 (45.2) 5(29.4) 56 (35.7) 50(49.5) 
Total 91 57 13 11 22 16 31 17 157 101 
Clinical Subclinical 
 Genotype Phenotype Genotype Phenotype 
Typeable(%) 31(72.1) 14(45.2) 53(58.2) 27(50.9) 
NT(%) 12(27.9) 17(54.2) 38(41.8) 26(49.1) 
Total 43 31 91 53 
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genotyped as cap5 and cap8 (63%), and from these isolates 27 
(50.9%) and 26 (49.1) were serotypeable and non serotypeable, 
respectively. 
Prevalence of isolates expressing CP5 and CP8 in this 
study (32.2%) was lower than those observed in most previous 
reports of other countries (6, 15, 23). A previous study carried 
out in Argentina, including 195 isolates, demonstrated that only 
14% could be typed by specific antisera against CP5 or CP8 
(21). In the present study, a higher prevalence of isolates 
expressing CP5 than previously reported (21) was observed; 
however, the percent of isolates expressing CP8 was similar in 
both studies. Differences in proportion of isolates expressing 
CP5 between studies can be explained mainly by the isolates 
geographical origin and the time frame of both studies. While 
most isolates from the previous study belonged to Buenos 
Aires province, S. aureus isolates included in the present 
investigation were obtained from the four main dairy provinces 
of Argentina. In addition, in the present study, to avoid bias 
produced by clonal dissemination, we included a maximum of 
3 isolates per dairy farm to assure bacterial isolate diversity 
within each geographical area considered. 
The low proportion of phenotype expression with respect 
to genotype presence was also reported in bovine mastitis 
isolates from Europe and USA (23). Genotype-phenotype 
disparity could indicate a restriction in phenotype expression 
due to differences between in vivo vs in vitro culture conditions 
(16, 17). This implies that conventional phenotypic evaluation 
can underestimate isolates ability to express CP in vivo. In 
addition, genotype-phenotype disparity could be due to the fact 
that some isolates carry cap genes but lack capsule expression 
due to mutations within capsule genes (1). 
We found no association between genotype or phenotype 
and clinical origin of the isolate. In a previous study a 
significant association between CP8 expression and mastitis 
clinical manifestations was observed only for isolates from 
Ireland and Iceland (23). Recent studies have shown an 
association between S. aureus genotypes and IMI clinical and 
epidemiological features (4, 7); however associations in these 
latter cases were established with patterns including several 
rather than individual genes (4). 
Presence of CP alone is considered to be insufficient to 
generate a protective immune response; however, their 
inclusion in a multicomponent vaccine would be useful to 
improve control of S. aureus IMI (18, 19, 22). In addition, 
relevance of CP as candidates for generating protective 
responses is underscored by the fact that a commercial vaccine 
currently available for S. aureus mastitis control contains 
capsulated strains expressing 3 serotypes of CP present among 
the population of bovine isolates in USA (10). Sixty four 
percent of the isolates evaluated in this study carried cap5 and 
cap8 genes, which emphasizes the importance of including 
these components for rational design of mastitis vaccines. 
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